Expedition Therapeutics announced an oversubscribed $115 million Series B financing to advance its next-generation DPP1 inhibitor for COPD. The oversubscription suggests strong investor appetite, supporting continued R&D momentum for the program.
Expedition Therapeutics announced an oversubscribed $115 million Series B financing to advance its next-generation DPP1 inhibitor for COPD. The oversubscription suggests strong investor appetite, supporting continued R&D momentum for the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
